Paper40134277
Immunotherapy for hypertensive end-organ damage: a new therapeutic strategy.
Xu Z and 3 others. Essays Biochem, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Immunotherapy for hypertensive end-organ damage: a new therapeutic strategy. Papers, record 40134277. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40134277
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypertension | Major topic |
| Immunotherapy | Major topic |
| Humans | |
| Animals |
Source PubMed
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38882290 | Role of plasmacytoid dendritic cells in vascular dysfunction in mice with renovascular hypertension. | Heliyon | 2024 | https://conductscience.org/library/papers/38882290 | PubMed |
| 2 | 29378857 | Myeloid CD11c+ Antigen-Presenting Cells Ablation Prevents Hypertension in Response to Angiotensin II Plus High-Salt Diet. | Hypertension | 2018 | https://conductscience.org/library/papers/29378857 | PubMed |
| 3 | 17143175 | A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. | J Hypertens | 2007 | https://conductscience.org/library/papers/17143175 | PubMed |
| 4 | 17938380 | Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension. | Hypertension | 2007 | https://conductscience.org/library/papers/17938380 | PubMed |
| 5 | 21224080 | Natural regulatory T cells control coronary arteriolar endothelial dysfunction in hypertensive mice. | Am J Pathol | 2011 | https://conductscience.org/library/papers/21224080 | PubMed |
| 6 | 38778172 | Immunological insights into hypertension: unraveling triggers and potential therapeutic avenues. | Hypertens Res | 2024 | https://conductscience.org/library/papers/38778172 | PubMed |
| 7 | 33488583 | Combination Treatment With Metformin and Tacrolimus Improves Systemic Immune Cellular Homeostasis by Modulating Treg and Th17 Imbalance. | Front Immunol | 2020 | https://conductscience.org/library/papers/33488583 | PubMed |
| 8 | 35704473 | Update on Immune Mechanisms in Hypertension. | Am J Hypertens | 2022 | https://conductscience.org/library/papers/35704473 | PubMed |
| 9 | 37664577 | A new immune disease: systemic hypertension. | Clin Kidney J | 2023 | https://conductscience.org/library/papers/37664577 | PubMed |
| 10 | 38545112 | Mechanisms of inflammation modulation by different immune cells in hypertensive nephropathy. | Front Immunol | 2024 | https://conductscience.org/library/papers/38545112 | PubMed |
| 11 | 38047378 | CD4+ T-Cell Legumain Deficiency Attenuates Hypertensive Damage via Preservation of TRAF6. | Circ Res | 2024 | https://conductscience.org/library/papers/38047378 | PubMed |
| 12 | 38483840 | Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy. | ACS Nano | 2024 | https://conductscience.org/library/papers/38483840 | PubMed |
| 13 | 36958796 | Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. | Ann Rheum Dis | 2023 | https://conductscience.org/library/papers/36958796 | PubMed |
| 14 | 21817097 | Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. | Arterioscler Thromb Vasc Biol | 2011 | https://conductscience.org/library/papers/21817097 | PubMed |
| 15 | 33868284 | Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases. | Front Immunol | 2021 | https://conductscience.org/library/papers/33868284 | PubMed |
| 16 | 29969833 | Hypertension: a new treatment for an old disease? Targeting the immune system. | Br J Pharmacol | 2019 | https://conductscience.org/library/papers/29969833 | PubMed |
| 17 | 7068177 | The mosaic theory 32 years later. | Hypertension | 1982 | https://conductscience.org/library/papers/7068177 | PubMed |
| 18 | 35998751 | Endoplasmic reticulum stress: A common pharmacologic target of cardioprotective drugs. | Eur J Pharmacol | 2022 | https://conductscience.org/library/papers/35998751 | PubMed |
| 19 | 38821150 | The current landscape of antifibrotic therapy across different organs: A systematic approach. | Pharmacol Res | 2024 | https://conductscience.org/library/papers/38821150 | PubMed |
| 20 | 38686582 | Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective. | Hypertension | 2024 | https://conductscience.org/library/papers/38686582 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41155215 | Immunology of Hypertension: Pathophysiological and Therapeutic Aspects. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41155215 | PubMed |
| 40922600 | Immunomodulation: precision targeting for restoring immune homeostasis and therapeutic applications. | Essays Biochem | 2025 | https://conductscience.org/library/papers/40922600 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40134277
GET https://conductscience.org/api/papers/v1/40134277/references?page=2